Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06947304 · ClinicalTrials.gov registry record · Phase 1
Evaluation of Miricorilant on Liver Fat in Patients With MASLD
A Phase 1 study of Non-alcoholic Steatohepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD), sponsored by Corcept Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT06947304: Recruiting Phase 1 study of Non-alcoholic Steatohepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD), sponsored by Corcept Therapeutics.
NCT06947304 is a Phase 1 study of Non-alcoholic Steatohepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD) that is actively recruiting participants, run by Corcept Therapeutics. The registered enrollment target is 8 participants, below the 196-participant average among 16 other Non-alcoholic Steatohepatitis (NASH) trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06947304, a Phase 1 study of Non-alcoholic Steatohepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD), is actively recruiting participants, sponsored by Corcept Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
A Phase 1, Open-Label Study Evaluating the Effect of Miricorilant on Hepatic Lipids in Patients with Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Conditions Studied
Interventions
- DRUG Miricorilant
Study Locations (1)
Missouri
- University of Missouri - Columbia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2025-08-22 |
| Est. Completion | 2026-05 |
| Phase | Phase 1 |
What NCT06947304 shows while recruiting
NCT06947304 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 196-participant average among 16 other Non-alcoholic Steatohepatitis (NASH) trials with a reported enrollment target (96% lower).
The record links to 4 conditions, with Non-alcoholic Steatohepatitis (NASH) appearing as the primary indexed condition, and to 1 intervention - of which Miricorilant is the first listed.
NCT06947304 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT06947304 about?
NCT06947304 is a clinical study titled "Evaluation of Miricorilant on Liver Fat in Patients With MASLD". A Phase 1, Open-Label Study Evaluating the Effect of Miricorilant on Hepatic Lipids in Patients with Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)
What is the current status of trial NCT06947304?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2025-08-22. Estimated completion is 2026-05.
What conditions does trial NCT06947304 study?
This clinical trial studies the following conditions: Non-alcoholic Steatohepatitis (NASH), Non-Alcoholic Fatty Liver Disease (NAFLD), Metabolic Dysfunction-Associated Steatohepatitis (MASH), Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
What interventions are being tested in trial NCT06947304?
The interventions under investigation include: Miricorilant (DRUG).
Who is sponsoring clinical trial NCT06947304?
This trial is sponsored by Corcept Therapeutics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06947304 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-alcoholic Steatohepatitis (NASH)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06947304's enrollment target sits among peer trials
8 17th of 16 the lowest of 16 other Non-alcoholic Steatohepatitis (NASH) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-alcoholic Steatohepatitis (NASH) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Assess Safety, Tolerability, PK and PD of AZD2693 in Non-alcoholic Steatohepatitis Patients
COMPLETED · Phase 1
-
Blood Collection Biorepository for Liver Disease Research
RECRUITING
-
Non-alcoholic Fatty Liver Disease Parametric PET (FLiPP) Study
ACTIVE NOT RECRUITING
-
A Physiologic Analysis of Endoscopic Sleeve Gastroplasty (ESG)
ACTIVE NOT RECRUITING · NA
-
A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy and Safety of Rencofilstat in Subjects With NASH and Advanced Liver Fibrosis
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI